Daré Bioscience (NASDAQ:DARE) reported a narrower second-quarter loss and outlined its transition toward commercial operations, following the June launch of its first directly marketed product, Flora Sync LF5. The company also said it expects prescription dispensing for its DARE to PLAY sildenafil cream to begin during the third quarter.
Chief Executive Officer Sabrina Martucci Johnson said the company is adding commercial execution to its development-focused strategy. Daré’s approach includes commercializing proprietary formulations through 503B compounding while also pursuing FDA approval for selected products, as well as marketing certain consumer health products that do not require prescriptions.
Commercial Portfolio Expands
Flora Sync LF5, launched in June under Daré’s DARE to RESTORE line, is a non-hormonal probiotic vaginal capsule sold without a prescription. The product is intended to support vaginal microbiome balance, moisture and comfort, and uses a proprietary form of Lactobacillus fermentum LF5. Johnson said the product was evaluated in a randomized clinical study involving 100 women, with the results published in a peer-reviewed journal.
Because Flora Sync LF5 sales began in July, the product did not contribute to second-quarter revenue, Chief Accounting Officer MarDee Haring-Layton said. The company began recognizing revenue from Flora Sync LF5 in July.
Daré is also preparing to dispense DARE to PLAY sildenafil cream, a proprietary topical formulation intended for women experiencing low or no sexual arousal. The company plans to make the product available by prescription through the 503B compounding pathway while continuing to pursue a 505(b)(2) regulatory pathway toward potential FDA approval.
Johnson said interested customers can already begin obtaining prescriptions, and the company has seen prescriptions written across different geographies, through both office-based providers and telehealth providers, as well as repeat prescribing activity from providers. Dispensing is targeted to begin in the current quarter.
The company has priced DARE to PLAY at $99 per tube, which it said provides about 10 uses. Johnson cited an estimated U.S. population of 20 million women with symptoms of low or no sexual arousal and said there is no FDA-approved treatment specifically indicated for female sexual arousal disorder.
Daré’s commercial infrastructure includes the DARE Health Hub, a digital platform intended to provide education, product access, telehealth connectivity, fulfillment and ongoing customer engagement. The company also recently announced a collaboration with women’s health telehealth platform MyMenopauseRx, through which women may receive prescriptions for DARE to PLAY.
Johnson said Daré will assess early commercialization through consumer adoption, provider adoption and commercial efficiency. The company’s 2026 goal is to establish performance benchmarks, customer relationships and repeatable processes that could support growth in 2027 and beyond.
Pipeline Programs Advance
Daré said Ovaprene, its investigational hormone-free monthly intravaginal contraceptive, continued progressing through a pivotal Phase III study. The company reported positive interim results during the quarter, and an independent Data Safety Monitoring Board recommended that the trial continue without modification.
The company expects to enroll enough participants in 2026 to achieve at least 2,500 menstrual cycles of exposure in 2027, supporting a planned top-line data announcement that year. Daré expects enrollment of between 450 and 500 participants, though it expects fewer than 250 completers.
In August, the FDA approved a protocol amendment removing the expectation that the study have 250 completers. However, Johnson said the agency continued to strongly recommend at least 250 completers and indicated that number could be necessary to adequately characterize Ovaprene’s safety. Daré said it believes the amended protocol could generate sufficient safety data for a premarket approval submission and plans to continue discussing the matter with the FDA.
The company also initiated a Phase II study of DARE-HPV in approximately 100 women with persistent high-risk HPV infection. Top-line results are expected in 2027. The study is supported by a contract funded by the Advanced Research Projects Agency for Health, or ARPA-H.
Additionally, Daré received notice of a second $1 million funding tranche from the National Institute of Allergy and Infectious Diseases for the DARE-HPV project, bringing total funding across the project period that began in December 2024 to $2 million.
For DARE to RECLAIM, an estradiol-progesterone intravaginal ring for menopause hormone therapy, the company said activities supporting commercial availability through the 503B compounding pathway are underway. Dispensing is targeted to begin in 2027.
Second-Quarter Financial Results
Daré ended the quarter with approximately $12.6 million in cash and cash equivalents as of June 30, 2026, along with a working-capital deficit of approximately $0.2 million. The company said current liabilities included approximately $15 million in deferred grant funding liabilities.
- Total second-quarter revenue was approximately $0.2 million, compared with negative $21,000 in the prior-year period. Revenue consisted of research and development services and royalty revenue.
- Selling, general and administrative expenses increased to approximately $2.6 million from $2.4 million, reflecting a non-cash write-down of previously deferred offering costs and investments in personnel and commercial readiness.
- Research and development expense declined to approximately $0.2 million from $1.4 million, which the company attributed to contra research-and-development expense from non-dilutive funding and lower spending across several programs.
- Net loss improved to approximately $3 million, compared with a loss of approximately $4 million in the second quarter of 2025.
Haring-Layton said Daré expects to begin recording revenue from DARE to PLAY in the third quarter and is targeting revenue from DARE to RECLAIM beginning in 2027, as it works toward a multi-product revenue profile.
About Dare Bioscience (NASDAQ:DARE)
Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.
In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.
